Merck Serono Ventures, Compugen Team Up On Drug Toxicity Biomarker Start-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.
You may also be interested in...
Prexton Therapeutics’ Parkinson’s Assets First to Emerge from Merck KGAA Restructuring
Prexton Therapeutics will be headquartered at the Eclosion incubator facility in Geneva and will advance mGluR compounds for Parkinson’s from the Merck Serono portfolio.
Deals Of The Week: Merck Serono/Compugen, Lilly/PrimeraDx, Biogen Idec/Isis
With the Supreme Court upholding the Patient Protection and Affordable Care Act, the pharma sector can look forward to a projected 8.8% increase in prescription drug spending in 2014.
Financings Of The Fortnight Ponders The Potential Of Mapping The Microbiome
Plus news on recent financial activity by Tesaro, Omeros, Neviah Genomics and Aegerion Pharmaceuticals.